Mankind Pharma IPO Particulars & Guidance @, India`s Oldest & the most Trusted Investment website for coming up IPOs. Operational since 8th December 1999, this is the Only Investment website in India, which has successfully completed 23 Years.
    mankind Pharma IPO particulars & guidance

    Mankind IPO listing at which price? The scrip will list on 9th May 2023. The grey market of the IPO witnessed sharp volatility. At one time the GMP had declined to Zero and there were no trades seen and then suddenly the GMP shot up to Rs. 73 and gradually improved to current level of Rs. 100/103. However, the traders show complete uncertainty about listing price. The way the promoters are Expert & energetic about the marketing, promotions and new launches, we expect positive listing, not just Rs. 1200, but there are all chances that on listing day, the scrip moves up to Rs. 1400 and yet there are large number of investors and traders who are skeptical of listing. They fear negative listing.
    Actual Listing: The scrip listed at Rs. 1300 and during the intraday, it moved up to Rs. 1393.65

    Whether you should apply in Mankind Pharma IPO?
    The management has formed habit of very fast and impressive growth. Highly capable of developing strong brands in Pharma and FMCG businesses. Grown organically and is the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in the Financial Year 2022. At a first glance, the price may appear to be high, grey market fancy is also not so strong and yet, the IPO is very very reasonably price and will bring in impressive returns if you remain invested for 9 months.
    Apply with full force.
    Listing gains are also expected.

    Who are the Anchor Investors of Mankind Pharma?
    Mankind Pharma raised Rs 1,298 crore from 77 anchor investors.

    The marquee investors that participated in the offer included Canada Pension Plan, Government of Singapore, Monetary Authority of Singapore, Goldman Sachs, Fiam Group Trust, Blackrock Global Funds, Abu Dhabi Investment Authority, Nomura Funds, Morgan Stanley, and Neuberger Berman Emerging Markets Equity Fund. HDFC Trustee, SBI Mutual Fund, Fidelity Investment, Motilal Oswal Mutual Fund, Nippon Life India, Axis Mutual Fund, Kotak Mutual Fund, Aditya Birla Sun Life Trustee, Franklin India, ICICI Prudential Life Insurance, HDFC Life Insurance, SBI Life Insurance, Tata Mutual Fund, and Kotak Mahindra Life Insurance also made an investment in the company via anchor book.

    What is the current grey market premium for Mankind Pharma IPO ?
    On Thursday, the grey market swung into action with GMP of Rs. 33 and within few minutes, the premium moved up to Rs. 40 and now on Friday, the GMP has shot up to Rs.100. Strong volume is seen for Retail Kostak and subject to.
    GMP:  Rs.128/133
    Rs.2 L application Rs. 9,000, (No trades)
    Rs. 10 L applications Rs. 12000 (No Trades)

    What is the Subscription Status Mankind Pharma IPO?
    On 27 April 2023 @ 5.00 (Closed)
    QIB          8011769   Shares, 49.16T
    NII:          6008827   Shares 3.80T
    RII:          14020596  Shares 0.92T
    Total:       28041192  Shares 15.32T

    Who are the promoters of Mankind Pharma?

    Mankind Pharma IPO Particulars & Guidance
    Very Elaborate Business Information: 

    Mankind Pharma is India’s fourth largest pharmaceutical company in terms of Domestic Sales and second largest in terms of sales volume for the Financial Year 2022. It is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It is focused on the domestic market, as a result of which its revenue from operations in India contributed to 97.60% of its total revenue from operations for the Financial Year 2022, which was one of the
    highest among peers identified by IQVIA.
    It has primarily grown organically and are the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in the Financial Year 2022.It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. It has created 36 brands in its pharmaceutical business that have each achieved over Rs 500.00 million in Domestic Sales in the Financial Year 2022.

    It has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market and over 80% of doctors in India prescribed its formulations during the Financial Year 2022, which has assisted it in establishing its brands in India. Its brands have enabled it to consistently generate the highest share of drug prescriptions in the IPM over the last five years. Further, in its Covered Markets, it was ranked second by market share for the Financial Year 2022.

    Mankind has experienced sustained growth and have consistently outperformed the growth of the IPM. Between the Financial Years 2020 and 2022, its Domestic Sales grew at a CAGR of approximately 16% from approximately Rs 60,647 million to approximately Rs 82,198 million, which is approximately 1.5 times that of the IPM, which grew at a CAGR of approximately 11%.
    Between the Financial Years 2020 and 2022, its Domestic Sales had the fastest growth (at a CAGR of
    approximately 16%) among the 10 largest corporates in the IPM by Domestic Sales. Its Domestic Sales ranking in the IPM improved from 8th in the Financial Year 2012 to 4th in the Financial Year 2022
    Its consistent growth has been backed by its capital efficiency, and it had RoCE of 35.86%, 30.41% and 25.50% for the Financial Years 2020, 2021 and 2022, respectively.

    Mankind Pharma is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients and respiratory.

    The company has made efforts to establish “Mankind” as a well-recognized brand in India. It has a demonstrated track record of creating brands with Domestic Sales of over Rs 1.00 billion and had the third highest number of such brands for any company in the IPM as of March 31, 2022.

    Mankind has a pan-India marketing presence, with a field force of 11,196 medical representatives and 3,195 field managers, as of March 31, 2022. It has also established a significant distribution network in India, and, during the Financial Year 2022, it sold its products to over 11,000 stockists and engaged with 75 C&F agents.

    The company operates 23 manufacturing facilities across India and had 2,181 manufacturing personnel as of March 31, 2022.
    Its formulations manufacturing facilities have a total installed capacity of 40.77 billion units across a wide range of dosage forms including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products, as of March 31, 2022. Several of the facilities have obtained approvals or certifications from, and are subject to inspections by, a range of regulatory bodies including the CDSCO and the USFDA.

    Through its R&D capabilities, it has developed a portfolio of differentiated products across several therapeutic areas. As of March 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with three units located in IMT Manesar, Gurugram, Haryana. One unit of
    this R&D center is recognized by the DSIR, and one unit is in compliance with WHO GMP and has been inspected by the USFDA.

    For more information, click
    Mankind Pharma IPO DRHP

    What are the Objects of Mankind Pharma IPO?
    This is only an offer for sale of Shares by the selling shareholders.

    Mankind Pharma IPO Details 
    IPO opens on  25 April ,2023 
    IPO closes on  27 April ,2023 
    Issue Type Book Built Issue IPO
    Issue Size 40,058,844 Sh /Rs 4326.36 Cr
    * Fresh Issue – Sh /Rs – Cr
    * Offer for Sale  40,058,844 Sh /Rs 4326.36 Cr
    Face Value per share: Rs. 1
    What is the Price Band of Mankind Pharma IPO? Rs. 1026-1080
    Retail Discount  Rs 0 per share
    Employee discount  Rs. 0 per share
    Retail Lot Size  13 Shares
    Listing will at  BSE, NSE
    Shares offered to Shares Rs. in Cr
    QIB (50 %)  20029422 2163.18
    NII (15 %)  6008827 648.96 
    RII (35 %)  14020595 1514.22
    Total Shares  40058844 4326.36 
    Retail portion will be oversubscribed by  1078507 Forms.
    How to Apply in Mankind Pharma IPO? Amount
    Min Retail Application 13 Sh Rs. 14040
    Max Retail Application  182 Sh Rs. 196560
    Small HNI (Min) application  195 Sh Rs. 210600
    Small HNI (Max) application 923 Sh Rs. 996840
    Big HNI Application 936 Sh Rs. 1010880

    Mankind Pharma IPO Particulars & Guidance

    Mankind Pharma IPO Tentative timetable
    IPO opens on  25 April 2023
    IPO Closes on  27 April 2023
    IPO Allotment on   3 May 2023
    Unblocking of ASBA   4 May 2023
    Credit of Shares  5 May 2023
    Listing on  9 May 2023
    Registered Office of the Company
    208, Okhla Industrial Estate, Phase-III, New Delhi 110 020, Delhi, India 
    Who are the lead managers of Mankind Pharma IPO?
    Kotak Mahindra Capital Company, Axis Capital Limited, IIFL Securities Limited, Jefferies India Private Limited, J.P. Morgan India
    Who is the Registrar Mankind Pharma IPO?
    KFin Technologies Limited
    Mankind Pharma IPO Financial & Analytical Ratios
    Year Total Income Net Profit EPS RoE
      Rs. in Cr Cr Rs. %
    2019-20 5975.65 1056.15 25.72 29.56
    2020-21 6385.38 1293.03 31.59 26.80
    2021-22  7977.58 1452.96 35.78 23.29
    Book Value of the Share on 31.03.2022 Rs. 153.65    
    Book Value of the Share after the FPO Rs.178.38    
    Offer Price at Cap   Rs. 1080    
    Key Performance Indicators of Mankind Pharma IPO
    Upper Price /last EPS 30.18
    Upper Price/Book Value Ratio 7.03
    Upper Price/BV after IPO  6.05

    Mankind Pharma IPO Particulars & Guidance
    Peer Comparison

    As on date of DRHP FV Total  PE
      Rs. Income Ratio of
        Rs. In Cr  
    The IPO Company 1 7782 30.18
    Sun Pharmaceuticals 1 38654 71.54
    Cipla  2 2,1763 28.18
    Zydus Lifesciences 1 15265 10.95
    Torrent Pharmaceutical  2 8508 66.25
    Alkem Laboratories  2 10634 23.03
    JB Chemicals 2 2424 39.48
    Eris Lifesciences  1 1347 19.10
    Ipca Laboratories 2 5829 22.38
    Abbott India 10 4919 56.19
    Glaxosmithkline Pharmaceuticals 10 3278 57.03
    Dabur India 1 1,08,887 54.55
    Procter & Gamble Health 10 11,144 42.27
    Zydus Wellness  10 20,091 31.11

    # This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.

    What is the latest Grey market premium and Subject to rates for Mankind Pharma IPO?
    Click latest updates. 
    >>Go to SME IPOs Section: Click

    >>Get Good Staff or Job, Click:
    >>Interested in Used Automobiles or vintage cars? Click:
    >>Get solid Guidance on Mutual fund Investments, Click:
    >>Study Stock Research Reports, Click:
    Interested in Crossword Puzzles? Click:

    5 Comments on “Mankind IPO, listed at Rs. 1300


      Fully Priced ho chahe. Lekin Grey market mein Majboot hai. Aur Grey market se kisi Operators ne hi maal uthaya hai.
      Listing ke din ₹1250 jaroor dikhayega.

    2. Srinivas

      Prices of this share could have been less. Although performance is good, as usual it is highly priced when compared with other peers. We all feel that there’s little room for the investors to earn after listed


    Leave a Reply

    Your email address will not be published. Required fields are marked *